The Oncology Institute (TOI) Q4 2025: 42% Revenue Growth Highlights Capitated Care Expansion
The Oncology Institute achieved a milestone with its first adjusted EBITDA profitable quarter driven by a 42% revenue surge, fueled by rapid growth in capitated care contracts and specialty pharmacy. The company’s hybrid care model and expanding payer partnerships position it for sustained profitability and scale in 2026 despite near-term margin pressures from delegated contracts.
Summary
- Capitated Care Scale-Up: Rapid expansion of delegated capitated contracts drives recurring revenue growth and operational leverage.
- Pharmacy Growth Leverages Integration: Specialty pharmacy revenue grows 71%, enhancing gross margins through improved prescription attachment.
- Profitability Path Confirmed: Positive adjusted EBITDA quarter and disciplined cost management signal trajectory toward sustained profitability.
Business Overview
The Oncology Institute (TOI) operates a value-based community oncology care model, generating revenue primarily from patient services and specialty pharmacy. Its business comprises fee-for-service oncology care, capitated care arrangements where TOI assumes financial risk for patient populations, and a specialty pharmacy segment that supports drug dispensing and clinical management. The company’s network includes employed and affiliated clinics across multiple states, focusing on integrated cancer care delivery.
Performance Analysis
TOI posted consolidated revenue of $142 million in Q4 2025, a 41.6% year-over-year increase driven by both patient services and specialty pharmacy segments. Patient services revenue rose 19.2% to $59.8 million, reflecting growth in both fee-for-service and capitated contracts, which now represent a significant portion of recurring revenue. Specialty pharmacy revenue surged 71.1% to $81.4 million, propelled by higher prescription volumes and improved attachment rates within TOI’s network clinics.
Gross profit expanded 55.2% to $22.7 million, with gross margin increasing approximately 140 basis points to 16%, supported by operational efficiencies in drug purchasing and utilization management. Patient services gross margin improved to 11.9% from 8.9%, while pharmacy gross margin rose to 18.3%, underscoring the benefits of scale in procurement and clinical pathways.
- Operational Leverage Evident: SG&A expenses declined 2% year-over-year and contracted to 19.7% of revenue, reflecting disciplined cost control amid growth.
- Adjusted EBITDA Turnaround: Achieved positive adjusted EBITDA of $147,000 in Q4, a significant improvement from a $7.8 million loss a year prior.
- Balance Sheet Strengthened: Cash balance of $33.6 million and positive operating cash flow of $3.2 million in Q4 provide financial flexibility.
Overall, the quarter demonstrates TOI’s successful scaling of its capitated care model and pharmacy integration, translating into improved margins and a clear path to profitability.
Executive Commentary
"The fourth quarter marked an important milestone, being our first profitable quarter as a public company from an adjusted EBITDA perspective. The biggest driver of this progress continues to be the expansion of our capitated care model, particularly through our delegated arrangements, which enables us to manage the oncology benefit more comprehensively while aligning incentives with our payer partners and delivering quality clinical outcomes."
Dan Vernick, Chief Executive Officer
"We ended the year with positive adjusted EBITDA in the fourth quarter, reflecting the operating leverage embedded in our model and the progress we've made towards sustainable profitability. Our pharmacy revenue grew 71% year-over-year, driven by higher prescription volumes and expanded pharmacy attachment within our clinics."
Rob Carter, Chief Financial Officer
Strategic Positioning
1. Accelerated Delegated Capitated Model Expansion
TOI’s growth is anchored in its delegated capitated care contracts, especially in Florida, where the partnership with Elevance is on track to more than double lives under management in 2026. Delegated contracts, while representing less than 5% of total capitated lives, account for about a third of capitated revenue due to higher per member per month (PMPM) payments and higher-utilizing populations. This model enhances financial predictability and clinical control, supporting margin expansion as scale increases.
2. Specialty Pharmacy Integration Driving Margin Expansion
The specialty pharmacy segment is a critical growth engine, with revenue reaching nearly $270 million for 2025 and contributing close to $50 million in gross profit. Improved prescription attachment rates within TOI clinics and reduced leakage to outside pharmacies reflect operational execution and integration benefits, which also support clinical outcomes and patient adherence.
3. Hybrid Care Delivery Model
TOI’s hybrid model combines employed clinics and an extensive network of independent providers, allowing flexibility in patient care delivery. This approach enables TOI to optimize medical loss ratios (MLR) while balancing capital efficiency and network breadth, appealing to payers seeking both cost control and access.
4. Technology and Operational Enhancements
The planned launch of a proprietary network provider portal in Q2 2026 aims to enhance provider engagement, utilization management, and formulary adherence. This digital platform is expected to improve medical loss ratios and drive ancillary service adoption, such as pharmacy attachment, further strengthening the integrated care model.
5. Leadership and Governance Strengthening
Adding experienced healthcare executives to the leadership team and board, including a Chief Clinical Officer and Chief Administrative Officer, along with board members with oncology and financial expertise, signals TOI’s commitment to scaling with operational rigor and governance best practices.
Key Considerations
TOI’s fourth quarter and full year results underscore the company’s transition from growth to profitability with a value-based care model that aligns clinical and financial incentives.
- Capitated Revenue Growth: Nearly 17% year-over-year growth in capitated revenue driven by new contracts and delegated models is central to sustainable margins.
- Margin Improvement Drivers: Operational efficiencies in pharmacy procurement and clinical utilization management underpin gross margin expansion.
- Cost Discipline vs. Growth Investment: SG&A leverage is evident but management signals continued investment in growth initiatives, balancing scale and expense control.
- Cash Flow Dynamics: Positive operating cash flow in Q4 reflects improved working capital management but free cash flow is expected to remain negative in early 2026 due to investments.
- Market Opportunity in Florida: Expanding Medicare Advantage penetration in Florida presents a multi-year growth runway supported by payer partnerships.
Risks
TOI faces risks from potential margin pressure during the ramp-up of delegated capitated contracts, as higher medical loss ratios may occur initially. Regulatory changes, reimbursement uncertainties, and competitive dynamics in oncology care and specialty pharmacy could impact profitability. Additionally, execution risks exist in scaling network provider engagement and technology deployment.
Forward Outlook
For Q1 2026, TOI expects adjusted EBITDA losses between $3 million and $1 million due to seasonality from deductible resets and lagged drug price reimbursement adjustments. Full year 2026 guidance projects revenue between $630 million and $650 million, gross profit of $97 million to $107 million, and adjusted EBITDA ranging from break-even to $9 million. Management anticipates free cash flow positivity by the end of 2026, driven by EBITDA growth and improved working capital.
Takeaways
TOI’s Q4 results reflect a pivotal inflection point as the company leverages its capitated care model and specialty pharmacy integration to drive growth and margin expansion.
- Capitated Model Scaling: The rapid expansion of delegated contracts, particularly in Florida, is transforming TOI’s revenue mix toward recurring, higher-margin streams.
- Operational Efficiency Gains: Pharmacy segment growth and procurement optimization contribute materially to gross margin improvement and operating leverage.
- Execution Focus for 2026: The launch of a provider portal and leadership enhancements indicate a strategic emphasis on sustaining growth while managing costs and provider engagement.
Conclusion
The Oncology Institute’s fourth quarter 2025 results validate its strategic pivot to value-based care with integrated oncology and pharmacy services. The company’s disciplined execution and expanding capitated footprint position it well for achieving sustainable profitability and long-term growth in a complex healthcare environment.
Industry Read-Through
TOI’s progress highlights the growing viability of delegated capitated models in oncology, combining clinical control with financial risk management. The specialty pharmacy integration underscores the importance of vertical alignment to improve margins and patient outcomes. Other oncology providers and payers may look to similar hybrid network models and technology-enabled utilization management to navigate reimbursement pressures and the evolving value-based care landscape.